Oxalic Acid

Oxalic Acid

SCHEMBL1401946

CCCC[Sn+3].CCCC[Sn+3].O=C([O-])C(=O)[O-].O=C([O-])C(=O)[O-].O=C([O-])C(=O)[O-]

nearest known ligand 0.52

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

OPRM1SLC6A4

The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
CA1 P00915 3/20 0.46
CES1 P23141 6/20 0.46
CES2 O00748 5/20 0.46
FFAR3 O14843 1/20 0.39
HDAC3 O15379 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC2 Q92769 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
FABP3 P05413 3/20 0.39
GPR84 Q9NQS5 1/20 0.39
CA2 P00918 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acetic Acid SCHEMBL674467 0.89 CES1 (0.46) CA1CES1CES2FFAR3HDAC3
Methacrylic Acid SCHEMBL6883217 0.85 TSHR (0.39) CA1CES1CES2FABP3GPR84
SCHEMBL6072819 0.82 CA1 (0.50) CA1CES1CES2CA2
Butyric Acid SCHEMBL11746797 0.82 FFAR3 (0.67) CA1CES1CES2FFAR3HDAC3
Fumaric Acid SCHEMBL2940732 0.82 CA1 (0.41) CA1CES1CES2FABP3
Fumaric Acid SCHEMBL2940726 0.82 CA1 (0.41) CA1CES1CES2FABP3
Thioglycolic Acid SCHEMBL7700486 0.82 CA1 (0.46) CA1CES1CES2FFAR3HDAC3
Acrylic Acid SCHEMBL11582286 0.80 TSHR (0.42) CA1CES1CES2FABP3
L-Lactic Acid SCHEMBL6072253 0.80 CA1 (0.48) CA1CES1CES2GPR84CA2
Trifluoroacetic Acid SCHEMBL6736795 0.80 CES2 (0.45) CA1CES1CES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8895773-B2 Manufacture and use of alkyl p-toluates INVISTA NORTH AMERICA S.A.R.L. (US) 2014-11-25 US disclosed
EP-2291347-A2 MANUFACTURE AND USE OF ALKYL P-TOLUATES Invista Technologies S.à.r.l. (CH) 2011-03-09 EP disclosed
US-20090286912-A1 MANUFACTURE AND USE OF ALKYL p-TOLUATES INVISTA NORTH AMERICA S.A R.L. (US) 2009-11-19 US disclosed
WO-2009137775-A2 MANUFACTURE AND USE OF ALKYL P-TOLUATES INVISTA TECHNOLOGIES S.A R.L. (CH) 2009-11-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286912-A1 MANUFACTURE AND USE OF ALKYL p-TOLUATES EP300, TERT, NAPEPLD CA1 4636/4885CES1 525/4885CES2 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.